These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 35812819)

  • 21. Efficacy and tolerability of the Subcutaneous Semaglutide for type 2 Diabetes patients: an updated systematic review and meta-analysis.
    Hu S; Su X; Fan G
    Diabetol Metab Syndr; 2023 Oct; 15(1):218. PubMed ID: 37891683
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Real-World Use of Oral and Subcutaneous Semaglutide in Routine Clinical Practice in the UK: A Single-Centre, Retrospective Observational Study.
    Roy Chowdhury S; Sadouki F; Collins E; Keen F; Bhagi R; Lim YSJ; Cozma SL; Bain SC
    Diabetes Ther; 2024 Apr; 15(4):869-881. PubMed ID: 38427165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Semaglutide Once-Weekly Persistence and Adherence Versus Other GLP-1 RAs in Patients with Type 2 Diabetes in a US Real-World Setting.
    Uzoigwe C; Liang Y; Whitmire S; Paprocki Y
    Diabetes Ther; 2021 May; 12(5):1475-1489. PubMed ID: 33837922
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis.
    Ma H; Lin YH; Dai LZ; Lin CS; Huang Y; Liu SY
    BMJ Open; 2023 Mar; 13(3):e061807. PubMed ID: 36882248
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of semaglutide on blood pressure in patients with type-2 diabetes: a systematic review and meta-analysis.
    Wu W; Tong HM; Li YS; Cui J
    Endocrine; 2024 Mar; 83(3):571-584. PubMed ID: 38097902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Advances in GLP-1 treatment: focus on oral semaglutide.
    Eliaschewitz FG; Canani LH
    Diabetol Metab Syndr; 2021 Sep; 13(1):99. PubMed ID: 34526121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of oral semaglutide in type 2 diabetes mellitus: A systematic review and meta-analysis.
    Li A; Su X; Hu S; Wang Y
    Diabetes Res Clin Pract; 2023 Apr; 198():110605. PubMed ID: 36871874
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Switching from Liraglutide or Dulaglutide to Subcutaneous Semaglutide on Glucose Metabolism and Treatment Satisfaction in Patients with Type 2 Diabetes: Protocol for a Multicenter, Prospective, Randomized, Open-Label, Blinded-Endpoint, Parallel-Group Comparison Study (The SWITCH-SEMA 1 Study).
    Nomoto H; Oba-Yamamoto C; Takahashi Y; Takeuchi J; Nagai S; Yokoyama H; Taneda S; Kurihara Y; Aoki S; Kameda H; Cho KY; Nakamura A; Atsumi T; Miyoshi H
    Diabetes Ther; 2021 Mar; 12(3):955-964. PubMed ID: 33491111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Perspectives on the Use of Subcutaneous and Oral Formulations of Semaglutide.
    Gallwitz B; Giorgino F
    Front Endocrinol (Lausanne); 2021; 12():645507. PubMed ID: 34267725
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy and safety of oral semaglutide in patients with type 2 diabetes and moderate renal impairment (PIONEER 5): a placebo-controlled, randomised, phase 3a trial.
    Mosenzon O; Blicher TM; Rosenlund S; Eriksson JW; Heller S; Hels OH; Pratley R; Sathyapalan T; Desouza C;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):515-527. PubMed ID: 31189517
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-World Effectiveness Analysis of Switching From Liraglutide or Dulaglutide to Semaglutide in Patients With Type 2 Diabetes Mellitus: The Retrospective REALISE-DM Study.
    Jain AB; Kanters S; Khurana R; Kissock J; Severin N; Stafford SG
    Diabetes Ther; 2021 Feb; 12(2):527-536. PubMed ID: 33367981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Weight loss with subcutaneous semaglutide versus other glucagon-like peptide 1 receptor agonists in type 2 diabetes: a systematic review.
    Stretton B; Kovoor J; Bacchi S; Chang S; Ngoi B; Murray T; Bristow TC; Heng J; Gupta A; Ovenden C; Maddern G; Thompson CH; Heilbronn L; Boyd M; Rayner C; Talley NJ; Horowtiz M
    Intern Med J; 2023 Aug; 53(8):1311-1320. PubMed ID: 37189293
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Semaglutide for the treatment of type 2 Diabetes Mellitus: A systematic review and network meta-analysis of safety and efficacy outcomes.
    Zaazouee MS; Hamdallah A; Helmy SK; Hasabo EA; Sayed AK; Gbreel MI; Elmegeed AA; Aladwan H; Elshanbary AA; Abdel-Aziz W; Elshahawy IM; Rabie S; Elkady S; Ali AS; Ragab KM; Nourelden AZ
    Diabetes Metab Syndr; 2022 Jun; 16(6):102511. PubMed ID: 35623229
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical potential of treatment with semaglutide in type 2 diabetes patients.
    Røder ME
    Drugs Context; 2019; 8():212585. PubMed ID: 31844422
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral Semaglutide Reduces HbA
    Pratley RE; Crowley MJ; Gislum M; Hertz CL; Jensen TB; Khunti K; Mosenzon O; Buse JB
    Diabetes Ther; 2021 Apr; 12(4):1099-1116. PubMed ID: 33660198
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cardiovascular safety outcomes of once-weekly GLP-1 receptor agonists in people with type 2 diabetes.
    Goldman JD
    J Clin Pharm Ther; 2020 Sep; 45 Suppl 1(Suppl 1):61-72. PubMed ID: 32910492
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and Safety of Oral Semaglutide in the Treatment of Type 2 Diabetes: A Meta-Analysis.
    Zhang L; Hua Z; Fang Z; Wei J; Lin Y
    J Clin Pharmacol; 2024 Jun; ():. PubMed ID: 38874130
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation and comparison of efficacy and safety of tirzepatide and semaglutide in patients with type 2 diabetes mellitus: A Bayesian network meta-analysis.
    Ding Y; Shi Y; Guan R; Yan S; Liu H; Wang Z; Li J; Wang T; Cai W; Ma G
    Pharmacol Res; 2024 Jan; 199():107031. PubMed ID: 38061595
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
    Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
    Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Greater time spent with HbA1c less than 7.0% with oral semaglutide versus oral comparators: An exploratory analysis of the PIONEER studies.
    Rosenstock J; Cariou B; Eliasson J; Frappin G; Kaltoft MS; Montanya E; Knop FK
    Diabetes Obes Metab; 2024 Feb; 26(2):532-539. PubMed ID: 37935463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.